Medpace Investors Alert: Lawsuit Deadline Approaching
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: Newsfilter
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 8, 2026, to participate in the ongoing securities fraud lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) concerning stock purchases between April 22, 2025, and February 9, 2026.
- Financial Performance Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, primarily due to the highest backlog cancellations in over a year, resulting in a 15.9% drop in stock price.
- False Statement Allegations: The lawsuit alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose adverse facts about the company's operations and prospects, which misled investors.
- Investor Rights Protection: Affected investors are encouraged to contact the Law Offices of Howard G. Smith to understand their legal rights and participate in the lawsuit to seek compensation, ensuring their interests are protected in the legal proceedings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 493.530
Low
462.00
Averages
569.17
High
660.00
Current: 493.530
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Medpace Holdings, Inc. is facing a class action lawsuit aimed at recovering losses for investors affected between April 22, 2025, and February 9, 2026.
- False Statements: The lawsuit alleges that defendants made overwhelmingly positive statements while concealing significant adverse facts regarding Medpace's backlog cancellation rate, leading to overly optimistic growth expectations among investors.
- Performance Decline: On February 9, 2026, Medpace reported a fourth-quarter book-to-bill ratio of 1.04, significantly below the guidance of 1.15, causing the stock price to plummet from $530.35 to $446.05, a decline of over 15.9%.
- Investor Rights: Affected investors have until June 8, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, highlighting the firm's commitment to protecting investor rights.
See More
Medpace Investors Alert: Lawsuit Deadline Approaching
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 8, 2026, to participate in the ongoing securities fraud lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) concerning stock purchases between April 22, 2025, and February 9, 2026.
- Financial Performance Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, primarily due to the highest backlog cancellations in over a year, resulting in a 15.9% drop in stock price.
- False Statement Allegations: The lawsuit alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose adverse facts about the company's operations and prospects, which misled investors.
- Investor Rights Protection: Affected investors are encouraged to contact the Law Offices of Howard G. Smith to understand their legal rights and participate in the lawsuit to seek compensation, ensuring their interests are protected in the legal proceedings.
See More
Medpace Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has initiated a class action lawsuit against Medpace in the Southern District of Ohio on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant investor dissatisfaction with the company's financial transparency.
- False Statements Uncovered: The complaint alleges that defendants misled investors by providing overly positive statements while concealing the true state of Medpace's backlog cancellation rate, leading to unrealistic growth expectations as the actual book-to-bill ratio was reported at 1.04, below the guidance of 1.15.
- Stock Price Plummet: Following the February 9, 2026 announcement of a 1.04 book-to-bill ratio, Medpace's stock price fell dramatically from $530.35 to $446.05 per share, a decline of over 15.9%, reflecting serious market concerns regarding the company's financial health.
- Legal Assistance Call: Wolf Haldenstein Adler Freeman & Herz LLP is urging affected investors to contact them to provide information for the investigation, emphasizing their 125 years of legal expertise in securities litigation aimed at seeking justice for investors.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace overstated its book-to-bill ratio for Q4 2025, reporting only 1.04 compared to the projected 1.15, resulting in a nearly 16% stock price drop upon the announcement, reflecting significant damage to the company's market credibility.
- Management Accountability: The lawsuit claims that Medpace executives failed to disclose the impact of order cancellations on the book-to-bill ratio throughout the class period, and their overly optimistic business outlook is deemed misleading, potentially exposing investors to greater financial risks.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, representing other investors in the lawsuit, showcasing the legal mechanisms in place to protect investor rights.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Medpace Holdings is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses when the market uncovered the truth, indicating that the company's public statements were materially misleading.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Uncertified Class Status: The class has not yet been certified, meaning investors are not represented by an attorney until certification occurs, emphasizing the importance of taking action to avoid becoming an absent class member.
See More
Medpace Investors Face Class Action Lawsuit Over Misleading Statements
- Class Action Initiated: The Portnoy Law Firm has filed a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026, with a deadline for lead plaintiff motions set for June 8, 2026, emphasizing the importance of legal rights for affected investors.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Medpace made false and/or misleading statements regarding its projected book-to-bill ratio for Q4 2025, failing to disclose the negative impact of cancellations, which misled investors about the company's financial health.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, resulting in a nearly 16% drop in stock price, indicating market disappointment and concerns over the company's future prospects.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss options for recovering losses, demonstrating the firm's commitment to protecting investor rights and providing support during this legal process.
See More
Medpace Holdings Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Medpace Holdings, Inc. is facing a class action lawsuit aimed at recovering losses for investors affected between April 22, 2025, and February 9, 2026.
- False Statements: The lawsuit alleges that defendants made overwhelmingly positive statements while concealing significant adverse facts regarding Medpace's backlog cancellation rate, leading to overly optimistic growth expectations among investors.
- Performance Decline: On February 9, 2026, Medpace reported a fourth-quarter book-to-bill ratio of 1.04, significantly below the guidance of 1.15, causing the stock price to plummet from $530.35 to $446.05, a decline of over 15.9%.
- Investor Rights: Affected investors have until June 8, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, highlighting the firm's commitment to protecting investor rights.
See More
Medpace Investors Alert: Lawsuit Deadline Approaching
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 8, 2026, to participate in the ongoing securities fraud lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) concerning stock purchases between April 22, 2025, and February 9, 2026.
- Financial Performance Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, primarily due to the highest backlog cancellations in over a year, resulting in a 15.9% drop in stock price.
- False Statement Allegations: The lawsuit alleges that defendants made materially false and misleading statements throughout the class period, failing to disclose adverse facts about the company's operations and prospects, which misled investors.
- Investor Rights Protection: Affected investors are encouraged to contact the Law Offices of Howard G. Smith to understand their legal rights and participate in the lawsuit to seek compensation, ensuring their interests are protected in the legal proceedings.
See More
Medpace Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has initiated a class action lawsuit against Medpace in the Southern District of Ohio on behalf of investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant investor dissatisfaction with the company's financial transparency.
- False Statements Uncovered: The complaint alleges that defendants misled investors by providing overly positive statements while concealing the true state of Medpace's backlog cancellation rate, leading to unrealistic growth expectations as the actual book-to-bill ratio was reported at 1.04, below the guidance of 1.15.
- Stock Price Plummet: Following the February 9, 2026 announcement of a 1.04 book-to-bill ratio, Medpace's stock price fell dramatically from $530.35 to $446.05 per share, a decline of over 15.9%, reflecting serious market concerns regarding the company's financial health.
- Legal Assistance Call: Wolf Haldenstein Adler Freeman & Herz LLP is urging affected investors to contact them to provide information for the investigation, emphasizing their 125 years of legal expertise in securities litigation aimed at seeking justice for investors.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misrepresentation Allegations: The lawsuit alleges that Medpace overstated its book-to-bill ratio for Q4 2025, reporting only 1.04 compared to the projected 1.15, resulting in a nearly 16% stock price drop upon the announcement, reflecting significant damage to the company's market credibility.
- Management Accountability: The lawsuit claims that Medpace executives failed to disclose the impact of order cancellations on the book-to-bill ratio throughout the class period, and their overly optimistic business outlook is deemed misleading, potentially exposing investors to greater financial risks.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, representing other investors in the lawsuit, showcasing the legal mechanisms in place to protect investor rights.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Medpace Holdings is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses when the market uncovered the truth, indicating that the company's public statements were materially misleading.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Uncertified Class Status: The class has not yet been certified, meaning investors are not represented by an attorney until certification occurs, emphasizing the importance of taking action to avoid becoming an absent class member.
See More
Medpace Investors Face Class Action Lawsuit Over Misleading Statements
- Class Action Initiated: The Portnoy Law Firm has filed a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026, with a deadline for lead plaintiff motions set for June 8, 2026, emphasizing the importance of legal rights for affected investors.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Medpace made false and/or misleading statements regarding its projected book-to-bill ratio for Q4 2025, failing to disclose the negative impact of cancellations, which misled investors about the company's financial health.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, resulting in a nearly 16% drop in stock price, indicating market disappointment and concerns over the company's future prospects.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss options for recovering losses, demonstrating the firm's commitment to protecting investor rights and providing support during this legal process.
See More
